Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Triple Negative Breast Neoplasms 1Solid Tumor 1Myeloid Malignancies 1Multiple Myeloma 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Colorectal Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 115fludarabine phosphate 67Mycophenolic Acid 62Etoposide 61Peripheral Blood Stem Cell Transplantation 58Tacrolimus 55Melphalan 48Filgrastim 48Busulfan 48Whole-Body Irradiation 47Doxorubicin 46Radiotherapy 42fludarabine 38Cyclosporine 38Brentuximab Vedotin 38Vinblastine 35Granulocyte Colony-Stimulating Factor 35Antilymphocyte Serum 30Methotrexate 29Dacarbazine 29Gemcitabine 28Rituximab 26Nivolumab 25Prednisone 24Bleomycin 24Vincristine 22pembrolizumab 21Carmustine 21Cytarabine 20thymoglobulin 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hodgkin Disease × magrolimab × Clear all
NCT04788043 2025-04-02

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

Stanford University

Phase 2 Active not recruiting
8 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡